Advertising disclosure: we may earn a commission when you buy through links on this site. How we make money

HomeTrials › NCT07357766

Obesity & weight · Phase 3 · Opening soon

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

NCT07357766 · Sponsor: Novo Nordisk A/S

What this trial means for you

This study is opening soon at 26 US sites. It's studying Cagrisema, Placebo CagriSema for overweight, obesity.

Who can joinAll sexes, 18 Years and older
Healthy volunteersNo — diagnosis required
What you'd takeCagrisema, Placebo CagriSema
Study length~17 months overall
Planned participants1,400
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance using a computer program, so neither participants nor study staff will know which treatment is given. The study will last for about one year.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * Male or female (sex at birth) * Age 18 years or above at the time of signing the informing consent. * Body Mass Index (BMI) is greater than or equal to (\>= ) 30.0 kilograms per square metre (kg/m\^2) or BMI \>= 27.0 kg/m\^2 with the presence of at least one obesity-related complication including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. Exclusion Criteria: * Glycosylated haemoglobin (HbA1c) \>= 6.5 % (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes. * Previous exposure to CagriSema in a clinical study.

Study sites by state

Alabama

  • Uni of Alabama at Birmingham — Birmingham
  • Cahaba Research — Pelham

California

  • Advanced Investigative Medicine, Inc. — Hawthorne
  • Southern Cal Clinical Research — Santa Ana
  • Encompass Clinical Research_Spring Valley — Spring Valley

Connecticut

  • Chase Medical Research LLC — Waterbury

Florida

  • NextPhase Research — Hollywood
  • Oceane 7 Medical & Research Center, Inc. — Miami
  • ForCare Clinical Research — Tampa

Georgia

  • EBGS Clinical Research Center, LLC — Snellville
  • Rophe Adult & Pediatric Medicine — Union City

Idaho

  • Rocky Mountain Diabetes and Osteoporosis Center — Idaho Falls

Illinois

  • PGM Research of Christie Clinic — Champaign

Michigan

  • Arcturus HC PLC Troy Med Res — Troy

Mississippi

  • Anointed Nephrology & HTN, LLC — Brookhaven

Nevada

  • Palm Research Center Inc. — Las Vegas
  • Palm Research Center Inc. — Las Vegas

New York

  • Weill Medical College of Cornell University — New York

Oklahoma

  • Alliance for Multispecialty Research — Norman

South Carolina

  • Tribe Clinical Research LLC — Greenville
  • Walker Family Care — Little River

Texas

  • Elligo Clin Res Centre — Austin
  • University of Texas Southwestern Medical Center — Dallas
  • Forefront Med Res Inst PLLC — Harlingen

Virginia

  • TPMG Clinical Research — Newport News

Washington

  • Capital Clin Res Ctr,LLC — Olympia

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently — always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in .env to activate this form.)

Keep researching on StudyBackedHealth